Five things for pharma marketers to know: Friday, April 21, 2017
1. Teva Pharmaceutical Industries debuted an asthma inhaler that will compete directly with GlaxoSmithKline's Advair. Teva also launched a generic version of its own inhaler. (Reuters)
2. Valeant Pharmaceuticals International priced its new injectable plaque psoriasis drug at $3,500 per month. The drugmaker purchased the rights to the drug, Siliq, from AstraZeneca. (MarketWatch)
3. Allowing the U.S. to import drugs from overseas would save patients money and prevent abusive pricing practices, a New York Times op-ed argued. “The safety fears, if not purely imaginary, are wildly exaggerated,” Tim Wu wrote. (NYT)
4. A woman whose husband committed suicide while taking a generic version of the depression drug Paxil was awarded $3 million by a jury, which decided that GlaxoSmithKline was responsible for not communicating that risk to her husband's doctor. GSK plans to appeal the decision. (AP)
5. Google is considering a move into the ad-blocking market. It could potentially add a feature to its Chrome web browser that filters out certain ads. (WSJ)
CORRECTION: An earlier version of this article incorrectly described when Teva's generic inhaler launched. It launched April 20.